There are two fundamentally different views of the role of elections in policy formation. In one view, voters can affect candidates' policy choices: competition for votes induces politicians to move toward the center. In this view, elections have the effect of bringing about some degree of policy compromise. In the alternative view, voters merely elect policies: politicians cannot make credible promises to moderate their policies, and elections are merely a means to decide which one of two opposing policy views will be implemented. We assess which of these contrasting perspectives is more empirically relevant for the U. S. House. Focusing on elections decided by a narrow margin allows us to generate quasi-experimental estimates of the impact of a "randomized" change in electoral strength on subsequent representatives' roll-call voting records. We find that voters merely elect policies: the degree of electoral strength has no effect on a legislator's voting behavior. For example, a large exogenous increase in electoral strength for the Democratic party in a district does not result in shifting both parties' nominees to the left. Politicians' inability to credibly commit to a compromise appears to dominate any competition-induced convergence in policy.

Background Despite rapid clinical translation and widespread enthusiasm, the therapeutic benefits of adult bone marrow cell (BMC) transplantation in patients with ischemic heart disease (IHD) continue to remain controversial. A synthesis of the available data is critical to appreciate and underscore the true impact of this promising approach. Methods and Results A total of 50 studies (enrolling 2,625 patients) identified by database searches through January 2012 were included. Weighted Mean Differences for changes in left ventricular (LV) ejection fraction (LVEF), infarct size, LV end-systolic volume (LVESV), and LV end-diastolic volume (LVEDV) were estimated using random effects meta-analysis. Compared with controls, BMC-treated patients exhibited greater LVEF (3.96%, 95% confidence interval (CI): 2.90, 5.02; P<0.00001), and smaller infarct size (–4.03%, CI: –5.47, –2.59; P<0.00001), LVESV (–8.91 ml, CI: –11.57, –6.25; P<0.00001), and LVEDV (–5.23 ml, CI: – 7.60, –2.86; P<0.0001). These benefits were noted irrespective of the study design (RCT vs. Cohort study) and the type of IHD (acute myocardial infarction vs. chronic IHD), and persisted during long-term follow-up. Importantly, the all-cause mortality, cardiac mortality, and the incidence of recurrent MI and stent thrombosis were significantly lower in BMC-treated patients compared with controls. Conclusions Transplantation of adult BMCs improves LV function, infarct size, and remodeling in patients with IHD compared with standard therapy, and these benefits persist during long-term follow-up. BMC transplantation also reduces the incidence of death, recurrent MI, and stent thrombosis in patients with IHD.

Objective.-To evaluate the long-term safety and tolerability of ubrogepant for the acute treatment of migraine. Background.-Ubrogepant is an oral, calcitonin gene-related receptor antagonist in development for the acute treatment of migraine. The efficacy of ubrogepant was demonstrated in 2 phase 3 trials in which a significant improvement was observed in migraine headache pain, migraine-associated symptoms, and ability to function.Methods.-This was a phase 3, multicenter, randomized, open-label, 52-week extension trial. Adults with migraine with or without aura entered the trial after completing one of 2 phase 3 lead-in trials and were re-randomized 1:1:1 to usual care, ubrogepant 50 mg, or ubrogepant 100 mg. Randomization to ubrogepant dose was blinded. Those randomized to usual care continued to treat migraine attacks with their own medication. The usual care arm was included in this trial to capture background rates of hepatic laboratory parameters and contextualize hepatic safety assessments. Safety and tolerability were the primary outcome measures. The safety population for the ubrogepant arms included all randomized participants who received at least 1 dose of treatment. All cases of alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevations of ≥3 times the upper limit of normal were adjudicated by an independent panel of liver experts who were blinded to dose.Results.-The safety population included 1230 participants (404 in the ubrogepant 50-mg group, 409 in the ubrogepant 100-mg group, and 417 in the usual care group). Participants were on average 42 years of age, 90% (1106/1230) female and 85% (1043/1230) white, with an average BMI of 30 kg/m 2 . Throughout the trial, 21,454 migraine attacks were treated with 31,968 doses of ubrogepant. Treatment-emergent adverse events (TEAEs) were reported by 268/404 (66%) participants receiving ubrogepant 50 mg and 297/409 (73%) receiving ubrogepant 100 mg. The most commonly reported TEAE was upper respiratory tract infection (<12%); findings were similar across dose groups. Treatment-related TEAEs were reported by 42/404 (10%) participants in the ubrogepant 50-mg group and 43/409 (11%) in the ubrogepant 100-mg group. Serious adverse events (SAEs) were reported by 9/404 (2%) participants in the ubrogepant 50-mg group and 12/409 (3%) participants in the ubrogepant 100-mg group. Twenty cases of ALT/AST levels of ≥3 times the upper limit of normal were reported and reviewed by an independent clinical adjudication committee of liver experts. There were no cases of Hy's Law.Conclusions.-Long-term intermittent use of ubrogepant 50 and 100 mg given as 1 or 2 doses per attack for the acute treatment of migraine was safe and well tolerated, as indicated by a low incidence of treatment-related TEAEs and SAEs and discontinuations due to adverse events in this 1-year trial.

Radiotelemetry is the standard method for monitoring wild turkey (Meleagris gallapavo) movements and habitat use. Spatial data collected using telemetry‐based monitoring are frequently inaccurate due to triangulation error. However, new technology, such as Global Positioning Systems (GPS) has increased ecologists' ability to accurately evaluate animal movements and habitat selection. We evaluated the efficacy of micro‐GPS backpack units for use on wild turkeys. We tested a micro‐GPS developed specifically for avian species that incorporated a GPS antenna with a lightweight rechargeable battery and a very high frequency (VHF) transmitter. We conducted a series of static tests to evaluate performance in varying types of vegetative canopy cover and terrain. After static testing, we deployed micro‐GPS on 8 adult male Rio Grande wild turkeys (M. g. intermedia) trapped in south Texas and 2 adult females trapped in the Texas panhandle. Micro‐GPS units collected 26,439 locations out of 26,506 scheduled attempts (99.7% fix rate) during static testing. Mean distance error across all static tests was 15.5 m (SE = 0.1). In summer 2009, we recovered micro‐GPS from 4 tagged males and both females to evaluate data collection. Units on males acquired approximately 2,500 locations over a 65‐day test period (94.5% fix rate). We recovered units from the 2 females after 19 days and 53 days; those units acquired 301 and 837 locations, respectively, for a 96% fix rate. Cost analysis indicated that VHF will be cost effective when 1 location per day is required up to 181 days, but micro‐GPS becomes less expensive as frequency of daily locations increases. Our results indicate that micro‐GPS have the potential to provide increased reliable data on turkey movement ecology and habitat selection at a higher resolution than conventional VHF telemetric methods. © 2011 The Wildlife Society.

No abstract